<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Laura Van Poelvoorde</style></author><author><style face="normal" font="default" size="100%">Xavier Saelens</style></author><author><style face="normal" font="default" size="100%">Isabelle Thomas</style></author><author><style face="normal" font="default" size="100%">Nancy Roosens</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza</style></title><secondary-title><style face="normal" font="default" size="100%">Trends in Biotechnology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antiviral resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">INFLUENZA</style></keyword><keyword><style  face="normal" font="default" size="100%">Next-generation sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Surveillance</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-04-2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">38</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Next-generation sequencing (NGS) can enable a more effective response to a wide range of communicable disease threats, such as influenza, which is one of the leading causes of human morbidity and mortality worldwide. After vaccination, antivirals are the second line of defense against influenza. The use of currently available antivirals can lead to antiviral resistance mutations in the entire influenza genome. Therefore, the methods to detect these mutations should be developed and implemented. In this Opinion, we assess how NGS could be implemented to detect drug resistance mutations in clinical influenza virus isolates.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>